Kiniksa Pharmaceuticals Interna
KNSA
Positions held
Your positionsKNSA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Kiniksa Pharmaceuticals operates in the growing specialty drug market, which is expected to expand as demand for innovative therapies increases.
- Revenue increased by 14% compared to the prior quarter, reaching $244 million.
- Gross margin was 54.2%, slightly down from 55% in the previous quarter.
- The company has a high trailing P/E ratio of 77.87, indicating potential overvaluation compared to earnings.
- In 2024, Kiniksa reported a negative operating margin of -10.78%, reflecting operational challenges.
- Net income for 2024 was -$43.193 million, highlighting ongoing financial difficulties.
Fundamentals
| Market cap | $6.14B | Enterprise value | $5.63B | Trailing P/E | 79.55 | Forward P/E | 48.69 |
| PEG | — | Price / book | 9.39 | Beta | 0.04 | Dividend yield | 0.00% |
| Revenue growth | 55.4% | Earnings growth | 30.4% | Gross margin | 54.5% | Operating margin | 11.2% |
| Profit margin | 9.6% | ROE | 14.0% | ROA | 8.0% | Debt / equity | 0.01 |
| Current ratio | 3.90 | Free cash flow | $126.14M | Analyst recommendation | strong_buy | Mean target | $98.00 |
| 52w high | $82.94 | 52w low | $35.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $244M | $214M | $202M | $181M | $157M |
| Op margin | 11.2% | 13.7% | 9.8% | 13.3% | 12.9% |
| Net income | $25.4M | $22.6M | $14.2M | $18.4M | $17.8M |
| Gross margin | 54.2% | 55.0% | 55.0% | 53.8% | 54.7% |
| Gross profit | $132M | $118M | $111M | $97.3M | $85.8M |
| Operating income | $27.2M | $29.3M | $19.8M | $24.0M | $20.2M |
- Revenue +14% vs prior quarter ($244M vs $214M).
- Gross margin 54.2% (was 55% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $678M | $423M | $270M | $220M | — |
| Op margin | 11.4% | -10.8% | -9.3% | 4.4% | — |
| Net income | $59.0M | -$43.2M | $14.1M | $183M | — |
| Gross margin | 54.7% | 85.6% | 87.6% | 89.6% | — |
| Gross profit | $370M | $362M | $237M | $197M | — |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
2026-09-17 · Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
2026-09-10 · Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
2026-09-04 · Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
2026-08-24 · TGTX Stock Outperforms 95% of Stocks. Here's Why.
2026-08-21 · Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
2026-08-21 · Three Biotech Stocks Stick Out With Their Stellar Charts
2026-08-15 · Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
2026-08-07 · Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
2026-08-03 · KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
2026-07-30 · Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
2026-07-30 · Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Price (daily)
Full chart · RSI · MACD · patterns